Introduction: Argentina's health system is characterized by its complexity and segmentation, and has 5 types of funders: The Social Security System (active workers and their family groups); the National Institute for Pensioners and Retirees 10% and the Federal Health Program (PROFE, non-contributory pensions) 48%; Pre-paid and Private Systems 8%; The Public Sector (PS) 34%. Regarding transplantation activities the Argentine State manages a program for the supply of immunosuppressant drugs (ID) for patients in the PS and PROFE, according to Transplantation Law No.24.193 and its Amendment No. 26.066, to Regulatory Decrees and corresponding Ministerial Resolutions which ensure the financing of these high cost drugs, and INCUCAI, the National Organ Procurement and Transplantation Institute, is in charge of coordinating and managing all actions inherent to their supply and distribution. Objectives: To describe a model for the public State supply of IS drugs oriented to vulnerable groups within the transplanted population, with no formal health coverage (PS-PROFE). Material and Methods: The Post-Transplant Follow-up National Program, since its implementation by Decree 1071/07 including Argentina's 24 provinces, and current data in the National Transplantation System (SINTRA) from 2007 to 2011 were considered. Results: The program was initiated in 2007 with a total of 703 patients and up to 31/12/2011 there were 2091 patients registered, which corresponds to 29% of the total number of living transplanted patients with a functioning implant. Its management and implementation is carried out by INCUCAI, through SINTRA, which is the on-line system that concentrates all transplantation activities. Drug Purchases are made by the National Health Ministry (NHM), the storing and distribution by Remediar (Program which distributes basic drugs to the 5000 Primary Care Centers), and delivery in all provinces through Provincial Procurement and Transplantation centers which are in charge of applying for them following the corresponding transplant team prescription. The purchase is carried out in a centralized way according to current regulations by generic name, which means the purchase of drugs at a lower price, and that adjust to the bioequivalence requirements established by the National Administration of Drugs, Food and Technology (ANMAT). Conclusions: Based on a National Program, carried out by national and provincial State Organizations, it was possible to improve accessibility to immunosuppressant treatments in post-transplanted populations which due to their socio-economic conditions are extremely vulnerable. On the other hand it allowed ensuring equity in the distribution of resources which enabled a better implant evolution and patient survival. That is to say that it is possible to carry out, in an efficient manner, a National Program among various management structures of the State funded with public funds from the National budget.